Market closed
Cytokinetics/$CYTK
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cytokinetics
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Ticker
$CYTK
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
423
Website
Cytokinetics Metrics
BasicAdvanced
$5.4B
-
-$5.38
0.79
-
Price and volume
Market cap
$5.4B
Beta
0.79
52-week high
$84.92
52-week low
$44.49
Average daily volume
1.1M
Financial strength
Current ratio
9.276
Quick ratio
9.215
Long term debt to equity
-5,457.911
Total debt to equity
-5,676.271
Interest coverage (TTM)
-6.48%
Management effectiveness
Return on assets (TTM)
-30.13%
Return on equity (TTM)
254.64%
Valuation
Price to revenue (TTM)
1,523.6
Price to book
-387.62
Price to tangible book (TTM)
-387.62
Price to free cash flow (TTM)
-12.049
Growth
Revenue change (TTM)
-58.81%
Earnings per share change (TTM)
-2.61%
3-year revenue growth (CAGR)
-46.94%
3-year earnings per share growth (CAGR)
20.03%
What the Analysts think about Cytokinetics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cytokinetics stock.
Cytokinetics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Cytokinetics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Cytokinetics News
AllArticlesVideos
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction
GlobeNewsWire·21 hours ago
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
GlobeNewsWire·1 week ago
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cytokinetics stock?
Cytokinetics (CYTK) has a market cap of $5.4B as of January 22, 2025.
What is the P/E ratio for Cytokinetics stock?
The price to earnings (P/E) ratio for Cytokinetics (CYTK) stock is 0 as of January 22, 2025.
Does Cytokinetics stock pay dividends?
No, Cytokinetics (CYTK) stock does not pay dividends to its shareholders as of January 22, 2025.
When is the next Cytokinetics dividend payment date?
Cytokinetics (CYTK) stock does not pay dividends to its shareholders.
What is the beta indicator for Cytokinetics?
Cytokinetics (CYTK) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.